GSK is poised to slash its back office headcount to help fund a £400m mega-campus in Cambridge in a move aimed a bolstering its pipeline.
Featured
Submit a story
Tell us your story.
Featured
Submit a story
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development
GSK announces plans to close main research hub in Stevenage
Pharma giant to relocate research hub to Cambridge in £400m move
GSK to shut Stevenage R&D hub under plans to open new site in Cambridge
GSK lays out plans to cut costs, pursue more late-stage drug trials
GSK prepares for patent cliff with $2.5B cost-cutting plan
GSK CEO targets $2.5B in cost savings from mature products, procurement, supply chain
Why Is GSK Stock Gaining Tuesday? - GSK (NYSE:GSK)
Pharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D site
Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically…
GSK is hoping all workers will relocate to either Cambridge or Ware
The move will impact around 1,800 staff currently based in Stevenage.
New GSK CEO Luke Miels outlined his strategy to help the company navigate a patent cliff and get on a path toward long-term…
The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of…
